作为助用户一臂之力的方法,本书介绍了以科学证据为基础的AHCC 的功能和用途。对AHCC在癌症预防和治疗方面的作用已经进行了重点研究,但AHCC 除了有抗癌作用外,因其免疫增强作用而
具有抗真菌,抗病毒,抗寄生等抗感染效果,此外它还显示出抗应激作用,增强抗癌药物疗效的作用,减轻免疫抑制等作用。另一方面,尽管详细作用机制尚未阐明,AHCC 通过修饰细胞间相互作用,抑制癌细胞浸润转移能力的效果已经得到认可。
Francisco Karkow, et al.
AHCC® in Sjögren’s Disease: One Bold Therapeutic Hypothesis
EC Microbiol. 2020; 16(1).
Zaure Zhaparkhanova, et al.
Nutritional Immunotherapy in Autoimmune Thyroid Disease: Preliminary Results
Endocrinology Quick Report. 2018; 2(50): 23-27.
Jean‑François Mallet, et al.
Eur J Nutr. 2016; 55(1): 139-46.
Loretta Olamigoke, et al.
Evid Based Complement Alternat Med. 2015; 2015: 508746.
Jun Takanari, et al.
J Evid Based Complementary Altern Med. 2015; 20(1): 28-34.
Mari Kogiso, et al.
Active Hexose Correlated Compound and T Cell Response in Hind – Limb – Unloaded BALB/c Mice
Int J Surg. 2015; 2(5): 32-38.
Abdelali Daddaoua, et al.
Food Chem. 2013; 136(3-4): 1288-95.
Tominori Kimura, et al.
Stabilization of human interferon-α1 mRNA by its antisense RNA
Cell Mol Life Sci. 2013; 70(8): 1451-67.
Won-Woo Lee, et al.
Cell Immunol. 2012; 275(1-2): 19-23.
Zhinan Yin, et al.
Hum Immunol. 2010; 71(12): 1187-90.
Naoyoshi Terakawa, et al.
Nutr Cancer. 2008; 60(5): 643-51.
Mari Kogiso, et al.
Active Hexose Correlated Compound and T Cell Response in Hind-Limb-Unloaded BALB/c Mice
Int J Surg. 2015; 2(5): 32-38.
Roghayeh Shahbazi, et al.
Int. J. Mol. Sci. 2023, 24(19), 14610
Katie M Love, et al.
J Trauma Acute Care Surg. 2013; 74(6): 1411-8.
Abeed H Chowdhury, et al.
Nutrients. 2019; 11(10): 2470.
Borja Ocón, et al.
Eur J Nutr. 2013; 52(2): 457-66.
Andrea Del Buono, et al.
World Cancer Research Journal. 2016; 3 (1): e652.
Zhiyun Cao, et al.
Nutr Res Pract. 2015; 9(2): 129-36.
Victoria L Gau, et al.
J Voice. 2022; 36(4): 441-442.
Judith A Smith, et al.
AHCC® Supplementation to Support Immune Function to Clear Persistent Human Papillomavirus Infections
Front Oncol. 2022; 12: 881902.
Manami Misu, et al.
Clinical Effects of AHCC® on High-risk Human Papillomavirus Infection and Secretory IgA
Japanese Pharmacology & Therapeutics. 2019; 47(11): 1921-1928.
Judith A Smith, et al.
Front Oncol. 2019; 9: 173.
Takeshi Katsuki, et al.
COVID-19 Pathology and Countermeasures ─Necessity of Severity Prevention Self-care─
Journal of Japan Health Medicine Association, 29(2): 142-152, 2020
Ali A. Rabaan, et al.
Ann Clin Microbiol Antimicrob. 2020; 19(1): 40
Brooke E Roman, et al.
Nutr Res. 2013; 33(1): 12-7.
Shoko Nogusa, et al.
Nutr Res. 2009; 29(2): 139-43.
Beatriz López-Cauce, et al.
Biomed Pharmacother. 2022; 150: 112937.
Mireia Tena-Garitaonaindia, et al.
Front Microbiol. 2022; 13: 814448.
Barry W Ritz
Nutr Rev. 2008; 66(9): 526-31.
María-Dolores Tabar, et al.
Leishmaniosis in a cat with chronic diarrhea as the only clinical manifestation
J Vet Intern Med. 2022; 36(2): 753-757.
María Auxiliadora Dea-Ayuela, et al.
Nucleotides and AHCC Enhance Th1 Responses In Vitro in Leishmania-Stimulated/Infected Murine Cells
Molecules. 2020; 25(17): 3918.
Rodolfo Oliveira Leal, et al.
JFMS Open Rep. 2018; 4(2): 2055116918811374.
Sergi Segarra, et al.
Parasit Vectors. 2018; 11(1): 103.
Sergi Segarra, et al.
Vet Parasitol. 2017; 239: 50-56.
Sergi Segarra.
Nutritional Modulation of the Immune Response Mediated by Nucleotides in Canine Leishmaniosis
Microorganisms. 2021; 9(12): 2601.
John Salerno, et al.
A Pilot Open-Label Study Assessing the Effects of AHCC® Supplementation on Lyme Disease Patients
Bioactive Compounds in Health and Disease. 2019; 2(11): 221-229.
Masaki Fujita, et al.
J Nutr Disorders Ther. 2015; 5: 4.
Shuhui Wang, et al.
J Nutr. 2009; 139(3): 598-602.
Hernan Aviles, et al.
Am J Surg. 2008; 195(4): 537-45.
Tesfaye Belay, et al.
Infect Immun. 2021; 89(5): e00786-20.
Tesfaye Belay, et al.
J Nutr Med Diet Care. 2015; 1(1): JNMDC-1-006.
Alba Pérez-Cantero, et al.
Pharmaceutics. 2019; 11(9): 456.
Sayam Thaiudom, et al.
The Medical News (Thailand). 2010; 325: 13-16.
Hiroaki Yanagimoto, et al.
Nutr Cancer. 2023; 75(1): 236-246.
Daisuke Hashimoto, et al.
Trials. 2022; 23(1): 135.
Yasuhiro Kuramitsu, et al.
Analysis of Cancer-Related Proteins Using Electrophoresis and Its Clinical Application
Electrophoresis Letters. 2021; 65(2): 23-27.
Shajedul Islam, et al.
Oncol Lett. 2021; 22(3): 654.
Daisuke Hashimoto, et al.
Surg Today. 2021; 51(11): 1872-1876.
Anarkhuu Bold-Erdene, et al.
Diagnosis. 2018; 83(3): 56-60.
Keisuke Kuhara, et al.
Anticancer Res. 2018; 38(11): 6107-6111.
Hiroaki Yanagimoto, et al.
Nutr Cancer. 2016; 68(2): 234-40.
Masayuki Tokunaga, et al.
Anticancer Res. 2015; 35(11): 6063-7.
Junya Nawata, et al.
Anticancer Res. 2014; 34(9): 4807-11.
Shigeyuki Suenaga, et al.
Anticancer Res. 2014; 34(1): 141-6.
Toshiya Kamiyama, et al.
Integr Cancer Ther. 2022; 21: 15347354211073066.
Zhiyun Cao, et al.
Nutr Res Pract. 2015; 9(2): 129-36.
Koji Wakame, et al.
Integr Cancer Sci Ther. 2017; 4(1).
Mehran Haidari, et al.
Life Sci. 2013; 93(25-26): 994-1003.
Sho Hangai, et al.
J Altern Complement Med. 2013; 19(11): 905-10.
Yoichi Matsui, et al.
Retrospective Study in Breast Cancer Patients Supplemented with AHCC
Inte J Integr Oncol. 2009; 3(2): 12-16.
Daisuke Nakamoto, et al.
Intern J Clin Med. 2012; 3: 361-367.
Kota Shigama, et al.
J Exp Ther Oncol. 2009; 8(1): 43-51.
Buxiang Sun, et al.
Cancer Epidemiol. 2009; 33(3-4): 293-9.
Jin Young Choia, et al.
Nutr Cancer. 2018; 70(1): 109-115.
Wineeya Suknikhom, et al.
Asian Pac J Cancer Prev. 2017; 18(3): 633-638.
Yoshiteru Sumiyoshi, et al.
Jpn J Clin Oncol. 2010; 40(10): 967-72.
Jeffrey Turner, et al.
Anticancer Drugs. 2009; 20(3): 215-6.
Francesca Paganelli, et al.
Pharmaceuticals. 2021; 14(12): 1325.
Maiko Takahashi, et al.
J Clin Biochem Nutr. 2019; 65(3): 203-208.
Hong-Jai Park, et al.
Front Immunol. 2022; 13: 875872.
Reiki Ishizuka, et al.
Pers Med Univers. 2012; 1(1): 39-44.
Reiki Ishizuka, et al.
International Journal of Integrative Medicine. 2010; 2(1): 98-111.
Lata Mathew, et al.
Integr Cancer Ther. 2017; 16(3): 300-307.
Rodney J Hunter, et al.
Int J Appl Res Nat Prod. 2011; 4(3): 6-14.
Andrea Del Buono, et al.
World Cancer Research Journal. 2016; 3 (1): e652.
Yusai Kawaguchi
Natural Medicine Journal. 2009; 1(1).
Kavin Fatehchand, et al.
PLoS One. 2017; 12(7): e0181729.
Dillip Kumar Parida, et al.
Intern J Clin Med. 2011; 2, 588-592.
Tamer A Badawi, et al.
Cairo Dental Journal. 2012; 28(1): 485-490.
Émilie A Graham, et al.
Cancer Biol Ther. 2017; 18(10): 765-774.
Bruna Corradetti, et al.
Integr Cancer Ther. 2019; 18: 1534735419866908.
Rosa Mistica Ignacio, et al.
Cytokine. 2015; 76(2): 131-137.
Zaure Zhaparkhanova, et al.
J Clin Med Kaz. 2021; 18(2): 66-71.
Yoshito Tanaka, et al.
Nitric Oxide. 2014; 40: 75-86.
Kosuke Matsui, et al.
Eur Surg Res. 2011; 47(4): 274-83.
Tadayoshi Okumura, et al.
Journal of the Japanese Society of Food Engineering. 2010; 30(3): 100-106.
Rachel E. Carlson, et al.
IJNF. 2018; 4(5): 32-36.
Larry W Coffer, et al.
J Integr Oncol. 2015; doi:10.4172/2329-6771.1000142.
Claire M Mach, et al.
J Soc Integr Oncol. 2008; 6(3): 105-9.
Marie-Francoise Doursout, et al.
Active hexose correlated compound modulates LPS-induced hypotension and gut injury in rats
Int Immunopharmacol. 2016; 39: 280-286.
Cristina Mascaraque, et al.
Active hexose correlated compound exerts therapeutic effects in lymphocyte driven colitis
Mol Nutr Food Res. 2014; 58(12): 2379-82.
Jun Takanari, et al.
Effects of AHCC® on Immune and Stress Responses in Healthy Individuals
J Evid Based Integr Med. 2018; 23: 2156587218756511.
Natalia V Mikhailichenko, et al.
FFHD. 2019; 9(3): 145-156.
Young-Ju Song, et al.
AHCC Supplementation Attenuates Muscle Atrophy via Akt Activation in Hindlimb-suspended Rat
Biotechnol Bioprocess Eng. 2019; 24: 476-482.
Yosuke Ueyama, et al.
J Surg Res. 2019; 243: 265-273.
Richi Nakatake, et al.
FFHD. 2016; 6(11): 702-717.
Tetsuya Okuyama, et al.
FFHD. 2013; 3(6):166-182.
Koji Wakame, et al.
Integr Mol Med. 2016; 3(3): 739-744.
Hyangkyoung Kim, et al.
Effect of Active Hexose Correlated Compound (AHCC) in Alcohol-Induced Liver Enzyme Elevation
J Nutr Sci Vitaminol. 2014; 60(5): 348-56.
Hajime Fujii, et al.
Genotoxicity and subchronic toxicity evaluation of Active Hexose Correlated Compound (AHCC)
Regul Toxicol Pharmacol. 2011; 59(2): 237-50.
Takehito Miura
Unwellness and Functional Foods: The Expected Role of Pharmacies
J Jpn Mibyou Assoc. 2022; 28(2): 43-48.
Jun-Young Choi
Complementary Therapy for Improvement of Quality of Life in Cancer Patients
J Korean Med Assoc. 2008; 51(5): 435-448.
Min Sun Shin, et al.
J Immunol Res. 2019; 2019: 3758576
Hiroshi Nishioka, et al.
Potentiating action of AHCC on natural immunity
Medical Science Digest. 2009; 35(6): 241-244.
Philippa J Cheetham, et al.
Diet and prostate cancer – a holistic approach to management
Arch Esp Urol. 2011; 64(8): 720-34.
Francesco Di Pierro, et al.
Minerva Gastroenterol Dietol. 2020; 66(2): 172-176.
Yutaka Horiuchi, et al.
Complementary and Alternative Medicine and AHCC®, GCP® in Companion Animals
Companion Animal Practice. 2012; 4: 53-57.
Takashi Nishizawa, et al.
Companion Animal Practice. 2011 Apr.
Mamoru Onuma, et al.
The supplementation therapy of caine dermatology in my hospital
Japanese Journal of Small Animal Practice. 2008; 27(6): 340-346.
Mikio Nishizawa, et al.
Assessment of anti-inflammatory effects of Japanese Kampo medicine versus functional foods
FFHD. 2019; 9(2): 79-91.
Hiroshi Nishioka, et al.
Various functions of a standardized extract of cultured Lentinula edodes mycelia (AHCC®)
Medical Science Digest. 2019; 45(2): 127-130.
Koji Wakame
Research and functional development of basidiomycete culture extracts
Agricultural biotechnology. 2017; 1(4): 438-442.
Catherine Ulbricht, et al.
J Diet Suppl. 2013; 10(3): 264-308.
Yasuo Kamiyama
AHCC: basic and clinical research
Journal of the society tropical resources technologists. 2011; 27(1): 1-8.
Shinil K Shah, et al.
J Parenter Enteral Nutr. 2011; 35(4): 449-58.
Barry W Ritz
Active Hexose Correlated Compound (AHCC) and Immune Outcomes in Humans: A Review
Natural Medicine Journal. 2011; 3(1): 3-7.
Takehito Miura, et al.
Basic and Clinical Studies on Active Hexose Correlated Compound
Biotechnology in Functional Foods and Nutraceuticals. 2010: 51-58.
Takehito Miura, et al.
Basic and Clinical Studies on AHCC —Recent Topics—
Japanese Journal of Complementary and Alternative Medicine. 2009; 6(1): 1-7.
Kentaro Kitadate
Augmentation of Anticancer Activity and Attenuation of Side Effect by AHCC
FOOD Style 21. 2008; 132: 69-72.
本文收集了AHCC和GCP的多个临床研究结果,展示了它们在不同癌症和健康问题中的有效性。
日本关西医科大学外科 上山泰男教授
Journal of Hepatology 37:78-86, 2002
肝细胞癌手术后使用 AHCC 的患者比对照组有明显更长的无复发期,并提高了生存率。手术后9年,AHCC组生存率达到50%,而对照组不到30%。
美国加州大学消化科 Nathan M. Bass 教授
Journal of Hepatology 37:147-150, 2002
试验表明,AHCC 显著提高了患者的生存率,延长了无复发期。功能食品需要严格的科学试验来验证其效果。
美国 Lexington 自然健康中心 James T. Belanger 主任医师
Townsend Letter for Doctors & Patients, 2005
34 名癌症患者分 4 组进行试验,服用 AHCC 后,NK 细胞活性平均提高 249%,显著优于其他保健食品。
美国德州大学和爱德森癌症中心
ISIM 国际统合医学会, 2011
AHCC 能预防或延迟 HPV 感染引起的人宫颈癌移植瘤的生长,表现出良好的抑制效果。
美国耶鲁大学 医学部 尹芝南教授
第 16 届 AHCC/GCP 国际研究会, 2008
服用 AHCC 可增强老年人的 CD4+ 和 CD8+ T 细胞的免疫反应,且在结束服用 30 天后仍然保持作用。
日本大阪大学院医学系研究科 井仓技教授
临床试验结果
在化疗过程中并用 AHCC,显著减少了白血球减少、中性粒细胞减少等毒副作用,并改善了患者的生活质量。
日本关西医科大学 外科 柳本泰明教授
临床试验结果
与对照组相比,服用 AHCC 的患者在贫血和炎症反应方面有明显改善,同时减少了化疗引起的味觉异常。
日本关西医科大学 外科 上山泰男教授
《癌症与营养》, 2008
通过双盲实验,服用 AHCC 的健康志愿者外周血免疫参数显著改善,特别是 CD4+ 和 NK 细胞活性有明显增强。
日本关西医科大学 外科 上山泰男教授
《自然医学杂志》, 2009
使用 AHCC 联合标准化疗后,胃癌和肠癌患者的免疫监测功能显著提升,特别是对于中期癌症患者效果更为显著。
哥伦比亚大学 Presbyterian 医疗中心泌尿外科 Aaron E. Katz 教授
The Journal of Alternative and Complementary Medicine 8(4):493-497, 2002
患者服用 GCP 后,PSA 显著下降,未发现癌细胞,且无毒副作用,显示出显著治疗效果。
韩国延世大学 Sun Yoon 教授
Journal of Medicinal Food 8(1):1-7, 2005
GCP 对并发糖尿病性网膜症的更年期女性具有明显的激素调节效果,并提高了抗氧化酶的活性。
日本田岛医院 石塚玲器教授
个性化 EBM 与 AHCC 和 GCP 长期使用观察, 11年
在 11 年的观察中,晚期肺癌和乳癌患者服用 AHCC 和 GCP 后,显著延长了生存时间并提高了生活质量。
所有系列产品均为膳食补充营养品,不是药物,不能代替药物治疗疾病。
© 2024 AMINO UP HONG KONG BIOTECHNOLOGY LIMITED All Rights Reserved
GCP ®是通过担子菌发酵大豆异黄酮制成的。它含有大量金雀异黄酮,一种非糖苷(糖苷配基型)异黄酮,根据实验实验数据发现:黄豆提取物与担子菌来源的多糖物质经过技术培养后具有复合作用。
根据实验室对照数据发现:GCP®机体吸收率比同类物质更高,为大豆提取物的五倍,临床研究上发现GCP®具有帮助调节女性激素、抑制肿瘤的血管新生、引起肿瘤细胞的自然死亡的作用。
紫苏提取物已被证明可作用于过敏反应途径中的多个点。 当身体产生一种特异性抗体 IgE(免疫球蛋白 E),对花粉、尘螨、食物等反应过度时,就会发生过敏。紫苏提取物通过抑制 IgE 产生来抑制过敏症状。
紫苏提取物通过抑制组胺的分泌来抑制过敏症状,并通过抑制TNF-α的产生来防止症状变得更严重或甚至演变成长期慢性过敏。
Amino Up采用的紫苏提取物原料由北海道多个签约农户种植。经过提取的紫苏提取物含有迷迭香酸和芹菜素、维琴宁2、木犀草素等黄酮类化合物作为抗过敏功能成分,并且不含易引起皮疹的紫苏醛或紫苏酮。
ETAS®是从芦笋中提取、浓缩对身体有益的活性成分而制成的功能性食品。原料是芦笋的底部,收获时切成相同的长度,有效利用未使用的成分。
ETAS®中含有的源自芦笋的脯氨酸-3-烷基二酮哌嗪(天冬脯氨酸)可促进 HSP70 的表达,可以有效调节自主神经系统的抗压力作用和改善睡眠质量。
HSP70是机体受到热、紫外线等外界刺激时体内产生的蛋白质,具有保护和修复受损细胞的功能。迄今为止对ETAS®进行的研究表明,它通过诱导HSP70的表达而具有“抗压力”、“改善睡眠质量”和“改善认知功能”等效果。
多酚是植物界广泛分布的成分,是具有抗氧化等功能的物质。然而,由于许多多酚是大分子聚合物,它们在体内的吸收率较低,并且它们在体内的抗氧化活性没有预期的那么高。
Oligonol®是世界上第一个成功降低这种多酚分子量,从而高效提升抗氧化吸收率的产品。
Oligonol® 的主要原料是从荔枝果实中提取的荔枝多酚。的主要成分是多酚。经过Amino Up专利技术生产后,以单体、低聚的二聚体、三聚体等低分子形式大量存在。 使得Oligonol®中的多酚物质的含量比普通多酚材料高2至8倍,并且能高效被人体吸收。
AHCC ®是Amino Up于1987年与日本东京大学联合研制的,它是选用北海道独特且珍贵的担子菌,通过Amino Up专利技术生产出的菌丝体中提取的一种多糖物质。AHCC从预培养到主培养在大罐中培养30至40天,然后经过浓缩、灭菌、冷冻干燥等一系列高科技处理,才形成成品。所有在全球销售的AHCC散装粉末仅在我们位于日本札幌的最先进的设施中生产,并严格控制质量。
产品特点:
• 富含乙酰化α-1.4葡聚糖(其它菌类产品无法获得该成分仅AHCC含有)和β葡聚糖
• 分子量非常小(小于5000道尔顿)在不增加肠胃负担情况下可以轻松被人体吸收
• 有足够的科学证据,已在40个国家应用了25年,改善近千万人的健康,可靠且安全。
• 至少发表了159篇论文,收录在PubMed数据库中。